PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34403880-1	2021	Tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, and ponatinib have significantly improved the life expectancy of Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) patients; however, resistance to TKIs remains a major clinical challenge.	ponatinib	78-87	phenylalanine hydroxylase	Homo sapiens	173-175	
35091541-0	2022	Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia.	ponatinib	11-20	phenylalanine hydroxylase	Homo sapiens	48-50